Research ArticleAccepted Article
A Decline in Walking Speed is Associated with Incident Knee Replacement in Adults with and at Risk for Knee Osteoarthritis
Matthew S. Harkey, Kate L. Lapane, Shao-Hsien Liu, Grace H. Lo, Timothy E. McAlindon and Jeffrey B. Driban
The Journal of Rheumatology June 2020, jrheum.200176; DOI: https://doi.org/10.3899/jrheum.200176
Matthew S. Harkey
From the Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester MA, USA, Division of Rheumatology, Allergy, and Immunology, Tufts Medical Center, Boston MA, USA, Medical Care Line and Research Care Line, Houston Health Services Research and Development Center of Excellence Michael E. DeBakey VAMC, Houston TX, USA, Section of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston TX, USA. These analyses were financially supported by a grant from the National Center For Advancing Translational Sciences (TL1-TR001454) and a grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number R01-AR065977. The OAI is a public-private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public use data set and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. This work was also supported in part by the Houston Veterans Affairs Health Services Research and Development Center of Excellence (HFP90-020). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. The funding sources had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; nor in the decision to submit the article for publication. Address correspondence to Matthew Harkey, PhD, Tufts Medical Center, Division of Rheumatology, Allergy, and Immunology, 800 Washington Street, Box 406, Boston, MA, 02111, USA. Email: mharkey@tuftsmedicalcenter.org
Kate L. Lapane
From the Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester MA, USA, Division of Rheumatology, Allergy, and Immunology, Tufts Medical Center, Boston MA, USA, Medical Care Line and Research Care Line, Houston Health Services Research and Development Center of Excellence Michael E. DeBakey VAMC, Houston TX, USA, Section of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston TX, USA. These analyses were financially supported by a grant from the National Center For Advancing Translational Sciences (TL1-TR001454) and a grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number R01-AR065977. The OAI is a public-private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public use data set and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. This work was also supported in part by the Houston Veterans Affairs Health Services Research and Development Center of Excellence (HFP90-020). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. The funding sources had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; nor in the decision to submit the article for publication. Address correspondence to Matthew Harkey, PhD, Tufts Medical Center, Division of Rheumatology, Allergy, and Immunology, 800 Washington Street, Box 406, Boston, MA, 02111, USA. Email: mharkey@tuftsmedicalcenter.org
Shao-Hsien Liu
From the Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester MA, USA, Division of Rheumatology, Allergy, and Immunology, Tufts Medical Center, Boston MA, USA, Medical Care Line and Research Care Line, Houston Health Services Research and Development Center of Excellence Michael E. DeBakey VAMC, Houston TX, USA, Section of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston TX, USA. These analyses were financially supported by a grant from the National Center For Advancing Translational Sciences (TL1-TR001454) and a grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number R01-AR065977. The OAI is a public-private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public use data set and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. This work was also supported in part by the Houston Veterans Affairs Health Services Research and Development Center of Excellence (HFP90-020). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. The funding sources had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; nor in the decision to submit the article for publication. Address correspondence to Matthew Harkey, PhD, Tufts Medical Center, Division of Rheumatology, Allergy, and Immunology, 800 Washington Street, Box 406, Boston, MA, 02111, USA. Email: mharkey@tuftsmedicalcenter.org
Grace H. Lo
From the Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester MA, USA, Division of Rheumatology, Allergy, and Immunology, Tufts Medical Center, Boston MA, USA, Medical Care Line and Research Care Line, Houston Health Services Research and Development Center of Excellence Michael E. DeBakey VAMC, Houston TX, USA, Section of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston TX, USA. These analyses were financially supported by a grant from the National Center For Advancing Translational Sciences (TL1-TR001454) and a grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number R01-AR065977. The OAI is a public-private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public use data set and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. This work was also supported in part by the Houston Veterans Affairs Health Services Research and Development Center of Excellence (HFP90-020). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. The funding sources had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; nor in the decision to submit the article for publication. Address correspondence to Matthew Harkey, PhD, Tufts Medical Center, Division of Rheumatology, Allergy, and Immunology, 800 Washington Street, Box 406, Boston, MA, 02111, USA. Email: mharkey@tuftsmedicalcenter.org
Timothy E. McAlindon
From the Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester MA, USA, Division of Rheumatology, Allergy, and Immunology, Tufts Medical Center, Boston MA, USA, Medical Care Line and Research Care Line, Houston Health Services Research and Development Center of Excellence Michael E. DeBakey VAMC, Houston TX, USA, Section of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston TX, USA. These analyses were financially supported by a grant from the National Center For Advancing Translational Sciences (TL1-TR001454) and a grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number R01-AR065977. The OAI is a public-private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public use data set and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. This work was also supported in part by the Houston Veterans Affairs Health Services Research and Development Center of Excellence (HFP90-020). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. The funding sources had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; nor in the decision to submit the article for publication. Address correspondence to Matthew Harkey, PhD, Tufts Medical Center, Division of Rheumatology, Allergy, and Immunology, 800 Washington Street, Box 406, Boston, MA, 02111, USA. Email: mharkey@tuftsmedicalcenter.org
Jeffrey B. Driban
From the Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester MA, USA, Division of Rheumatology, Allergy, and Immunology, Tufts Medical Center, Boston MA, USA, Medical Care Line and Research Care Line, Houston Health Services Research and Development Center of Excellence Michael E. DeBakey VAMC, Houston TX, USA, Section of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston TX, USA. These analyses were financially supported by a grant from the National Center For Advancing Translational Sciences (TL1-TR001454) and a grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number R01-AR065977. The OAI is a public-private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public use data set and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. This work was also supported in part by the Houston Veterans Affairs Health Services Research and Development Center of Excellence (HFP90-020). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. The funding sources had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; nor in the decision to submit the article for publication. Address correspondence to Matthew Harkey, PhD, Tufts Medical Center, Division of Rheumatology, Allergy, and Immunology, 800 Washington Street, Box 406, Boston, MA, 02111, USA. Email: mharkey@tuftsmedicalcenter.org
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
A Decline in Walking Speed is Associated with Incident Knee Replacement in Adults with and at Risk for Knee Osteoarthritis
Matthew S. Harkey, Kate L. Lapane, Shao-Hsien Liu, Grace H. Lo, Timothy E. McAlindon, Jeffrey B. Driban
The Journal of Rheumatology Jun 2020, jrheum.200176; DOI: 10.3899/jrheum.200176
Accepted manuscript
A Decline in Walking Speed is Associated with Incident Knee Replacement in Adults with and at Risk for Knee Osteoarthritis
Matthew S. Harkey, Kate L. Lapane, Shao-Hsien Liu, Grace H. Lo, Timothy E. McAlindon, Jeffrey B. Driban
The Journal of Rheumatology Jun 2020, jrheum.200176; DOI: 10.3899/jrheum.200176